IN2014DN05772A - - Google Patents

Info

Publication number
IN2014DN05772A
IN2014DN05772A IN5772DEN2014A IN2014DN05772A IN 2014DN05772 A IN2014DN05772 A IN 2014DN05772A IN 5772DEN2014 A IN5772DEN2014 A IN 5772DEN2014A IN 2014DN05772 A IN2014DN05772 A IN 2014DN05772A
Authority
IN
India
Prior art keywords
galectin
medicament
novel compounds
compounds
ligandsin
Prior art date
Application number
Other languages
English (en)
Inventor
Ulf Nilsson
Hakon Leffler
Balaram Mukhopadhyay
Vishal Rajput
Original Assignee
Galecto Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galecto Biotech Ab filed Critical Galecto Biotech Ab
Publication of IN2014DN05772A publication Critical patent/IN2014DN05772A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
IN5772DEN2014 2012-01-25 2013-01-24 IN2014DN05772A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12152413.6A EP2620443A1 (en) 2012-01-25 2012-01-25 Novel galactoside inhibitors of galectins
PCT/EP2013/051339 WO2013110704A1 (en) 2012-01-25 2013-01-24 Novel galactoside inhibitors of galectins

Publications (1)

Publication Number Publication Date
IN2014DN05772A true IN2014DN05772A (zh) 2015-04-10

Family

ID=47598867

Family Applications (1)

Application Number Title Priority Date Filing Date
IN5772DEN2014 IN2014DN05772A (zh) 2012-01-25 2013-01-24

Country Status (8)

Country Link
US (1) US9353141B2 (zh)
EP (2) EP2620443A1 (zh)
JP (1) JP6158840B2 (zh)
CN (1) CN104066743B (zh)
CA (1) CA2854986C (zh)
ES (1) ES2559857T3 (zh)
IN (1) IN2014DN05772A (zh)
WO (1) WO2013110704A1 (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU229352B1 (en) 1999-11-03 2013-11-28 Bristol Myers Squibb Co Medicament comprising the combination of metformin and glyburide
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
US9243021B2 (en) 2012-10-31 2016-01-26 Galecto Biotech Ab Galactoside inhibitor of galectins
CN104955471A (zh) * 2012-11-15 2015-09-30 塔夫斯大学 使用半乳糖凝集素蛋白抑制剂用于治疗、调节或预防受试者的眼部血管生成或者纤维化的方法、组合物以及试剂盒
WO2014100703A2 (en) 2012-12-20 2014-06-26 Henry Ford Health System Method for treating diastolic heart failure by inhibiting galectin-3
JP6735680B2 (ja) * 2014-07-09 2020-08-05 ガレクト バイオテック エービー ガレクチンの新規ハイブリッドガラクトシド阻害剤
CA2970062C (en) * 2015-01-30 2023-02-28 Galecto Biotech Ab Alpha-d-galactoside inhibitors of galectins
AU2017228365B2 (en) * 2016-03-04 2021-05-27 Galectin Sciences, Llc Selenogalactoside compounds for the prevention and treatment of diseases associated with galectin and the use thereof
CA3025867A1 (en) * 2016-07-12 2018-01-18 Galecto Biotech Ab Alpha-d-galactoside inhibitors of galectins
EP3484903A1 (en) * 2016-07-12 2019-05-22 Galecto Biotech AB Alpha-d-galactoside inhibitors of galectins
BR112019023722A2 (pt) 2017-05-12 2020-05-26 Galectin Sciences, Llc Compostos para a prevenção e tratamento de doenças e o uso dos mesmos
WO2019133878A1 (en) 2017-12-29 2019-07-04 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectin and galectin-3
US20210138080A1 (en) * 2018-06-29 2021-05-13 Glykos Biomedical Oy Conjugates
US11873317B2 (en) 2018-12-27 2024-01-16 Glycomimetics, Inc. Galectin-3 inhibiting c-glycosides
WO2020139962A1 (en) 2018-12-27 2020-07-02 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectin and galectin-3
US20230038373A1 (en) 2019-12-18 2023-02-09 Glykos Biomedical Oy Stabile conjugate

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100172D0 (sv) * 2001-01-22 2001-01-22 Ulf Nilsson New inhibitors against galectins
SE0401300D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel Galactoside Inhibitors of Galectins
SE0401301D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
ES2611206T3 (es) 2008-05-16 2017-05-05 Galecto Biotech Ab Derivados de di-(3-deoxi-3-1H-1,2,3-triazol-1-il)-beta-D-galacto-iranosil)sulfano como inhibidores de galectina-3
EP2424873B1 (en) 2009-04-28 2017-11-15 Galecto Biotech AB Novel galactoside inhibitors of galectins
CN104755088A (zh) 2012-10-31 2015-07-01 格莱克特生物技术公司 半乳凝集素-3的半乳糖苷抑制剂及其用于治疗肺纤维化的应用

Also Published As

Publication number Publication date
US20140336146A1 (en) 2014-11-13
JP6158840B2 (ja) 2017-07-05
CN104066743A (zh) 2014-09-24
CA2854986C (en) 2019-09-17
JP2015504909A (ja) 2015-02-16
CA2854986A1 (en) 2013-08-01
WO2013110704A1 (en) 2013-08-01
US9353141B2 (en) 2016-05-31
CN104066743B (zh) 2016-04-06
EP2807176A1 (en) 2014-12-03
EP2807176B1 (en) 2015-12-30
EP2620443A1 (en) 2013-07-31
ES2559857T3 (es) 2016-02-16

Similar Documents

Publication Publication Date Title
IN2014DN05772A (zh)
AU2012214029A8 (en) Rorgammat inhibitors
MD20140002A2 (ro) Indazoli
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
PH12015501116A1 (en) New indanyloxydihydrobenzofuranylacetic acids
PH12016500225A1 (en) Novel quinoline-substituted compound
MA33939B1 (fr) 5-alcynyl-pyrimidines
NZ705135A (en) Heteroaryl compounds and methods of use thereof
MX2013004491A (es) Boronatos como inhibidores de arginasa.
IN2014MN02459A (zh)
EA024702B8 (ru) Новые иммуномодуляторные и противовоспалительные соединения
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
PH12015500211A1 (en) 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
IN2015DN01151A (zh)
MX2014004858A (es) Compuestos de 3,4-diamino-3-ciclobuten-1,2-diona disustituidos utiles en el tratamiento de patologias mediadas por quimiocinas.
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
MX342924B (es) Nuevos compuestos disustituidos de 3,4-diamino-3-ciclobuteno-1,2-d iona para uso en el tratamiento de patologias mediadas por quimiocinas.
MX340577B (es) Inhibidor de fosfoinositida 3-quinasa con una porcion de enlace de cinc.
WO2012061754A3 (en) Compounds and methods for treating autoimmune diseases
MX349254B (es) Compuestos para el tratamiento del sindrome metabolico.
UA111628C2 (uk) Композиція для боротьби з хворобою рослини та її застосування
MX2014002988A (es) Proceso y composicion para inhibir la polimerizacion de compuestos de ciclopentadieno.
MX349548B (es) Compuestos de tienopirimidina.
TN2012000469A1 (en) Use of novel pan-cdk inhibitors for treating tumors
MX2012000177A (es) 2-carboxamida-cicloamino-ureas sustituidas.